drugset
drugset / Trial / NCT00594230

LBH589 in Refractory Myelodysplastic Syndromes (MDS)

NCT00594230 ↗

Phase 2 Terminated 26 enrolled SCRI Development Innovations, LLC Novartis Pharmaceuticals · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This will be a single arm Phase II study.

Timeline

Start
2008-01
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Panobinostat Small molecule 20 mg Oral
Subject Panobinostat Small molecule 30 mg Oral

Indications

myelodysplastic syndrome